Mindblown: a blog about philosophy.

  First Quarter 2021 Record Revenue of Approximately $28.9 Million Representing 466% Growth over First Quarter 2020 Announced Plans to Launch Two New Diagnostic Tests – SARS-CoV-2 Neutralization Antibody Detection Test and Next Generation Sequencing Test   BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung…

BOULDER, Colo.–(BUSINESS WIRE)–Apr. 26, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial results…

Blood-based NGS Test is Shown in Recent Publication to Provide Critical Data in 72 Hours; Launch Planned for First Half of 2022 BOULDER, CO, April 28, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add a blood-based 52-gene next generation sequencing…

Dr. Laura Peek and Dr. Sean Taylor presenting novel data on SARS-CoV-2 Neutralizing Antibody Testing; Commercial Launch Planned for Summer 2021 BOULDER, CO, April 26, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership with GenScript Biotech Corporation, a webinar to present…

Pulmonary Disease Expert, Dr. Susan Garwood, is Hosted by CHEST to Discuss Standardized Risk Assessment to Enhance Referral Patterns for Patients with Lung Nodules BOULDER, CO, April 22, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a webinar to discuss biomarkers and risk…

Findings to be Presented at AACR Annual Meeting Further Demonstrate the Utility of Protein Biomarker Data to Support Physicians in Patient Management BOULDER, CO, April 10 , 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will…

Diagnostic Test and Novel Methodologies Designed to Guide Patient Assessment and Treatment Strategies BOULDER, CO, April 6, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability…

Full Year 2020 Revenue Growth of 86% on Record Revenue of approximately $46 million BOULDER, Colo.–Mar. 16, 2021 — Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. “We had a…

Boulder, CO, March 9, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16. Biodesix’s management will host a conference…

BOULDER, CO, February 25, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021. The Healthcare Technology Report noted that the past twelve months,…